Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation
Open Access
- 23 November 2015
- journal article
- research article
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 14 (1) , 77-87
Abstract
Background Smoking cessation medications have been shown to yield higher success rates and sustained abstinence than unassisted quit attempts. In Japan, the treatments available include nicotine replacement therapy (NRT) and varenicline; however, unassisted attempts to quit smoking remain common. Objective The objective of this study was to compare the health and economic consequences in Japan of using pharmacotherapy to support smoking cessation with unassisted attempts and the current mix of strategies used. Methods A discrete-event simulation that models lifetime quitting behaviour and includes multiple quit attempts (MQAs) and relapses was adapted for these analyses. The risk of developing smoking-related diseases is estimated based on the duration of abstinence. Data collected from a survey conducted in Japan were used to determine the interventions selected by smokers initiating a quit attempt and the time between MQAs. Direct and indirect costs are assessed (expressed in 2014 Japanese Yen). Results Using pharmacotherapy (NRT or varenicline) to support quit attempts proved to be dominant when compared with unassisted attempts or the current mix of strategies (most are unassisted). The results of stratified analyses by age imply that smoking cessation improves health outcomes across all generations. Indirect costs due to premature death leading to lost wages are an important component of the total costs, exceeding the direct medical cost estimates. Conclusions Increased utilisation of smoking cessation pharmacotherapy to support quit attempts is predicted to lead to an increase in the number of smokers achieving abstinence, and provide improvements in health outcomes over a lifetime with no additional costs.Keywords
Funding Information
- Pfizer Japan Inc.
This publication has 31 references indexed in Scilit:
- Smoking Cessation Treatment and Outcomes Patterns Simulation: A New Framework for Evaluating the Potential Health and Economic Impact of Smoking Cessation InterventionsPharmacoEconomics, 2013
- Adult Mortality Attributable to Preventable Risk Factors for Non-Communicable Diseases and Injuries in Japan: A Comparative Risk AssessmentPLOS Medicine, 2012
- 2. How to Handle with ^|^quot;Unrelated Cost^|^quot; in Economic Evaluation?Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku, 2012
- A Discrete-Event Simulation of Smoking-Cessation Strategies Based on Varenicline Pivotal Trial DataPharmacoEconomics, 2011
- Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular DiseaseCirculation, 2010
- A Catalogue of EQ-5D Utility Weights for Chronic Diseases among Noninstitutionalized Community Residents in KoreaValue in Health, 2009
- Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trialThorax, 2008
- Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessationCost Effectiveness and Resource Allocation, 2008
- Mapping the EQ-5D Index from the SF-12: US General Population Preferences in a Nationally Representative SampleMedical Decision Making, 2006
- Trends in the Incidence, Mortality, and Survival Rate of Cardiovascular Disease in a Japanese CommunityStroke, 2003